Crocin

DB11874InvestigationalSmall molecule

Crocin has been investigated for the treatment of Hyperglycemia, Metabolic Syndrome, Hypertriglyceridemia, and Hypercholesterolemia.

Mechanism: Pharmacologically active on Microtubule-associated protein tau and Tubulin
Curator reviewed
Formula / weight: C₄₄H₆₄O₂₄ · 976.972 g/mol (avg)

Resolves to

Compound

UNII877GWI46C2CAS42553-65-1ChEMBLCHEMBL446785ChEBI79068PubChem5281233KEGGC08589

Clinical / RWD

RxNorm2262278

Structure

InChIKeySEBIKDIMAPSUBY-RTJKDTQDSA-NSMILES

C\C(\C=C\C=C(/C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O

Targets

P10636MAPT

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Crocin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account